Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response

Endocrine-Related Cancer

Volumn 17, Issue 3, 2010, Pages

  Riggins, Rebecca B ^a   Mazzotta, Mary M ^a   Maniya, Omar Z ^a   Clarke, Robert ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR; CISPLATIN; DOCETAXEL; DOXORUBICIN; ESTROGEN RELATED RECEPTOR ALPHA; ESTROGEN RELATED RECEPTOR GAMMA; FLUOROURACIL; FULVESTRANT; GEFITINIB; LIVER RECEPTOR HOMOLOG 1; ORPHAN NUCLEAR RECEPTOR; PACLITAXEL; TAMOXIFEN; TRANSCRIPTION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

BREAST CARCINOGENESIS; CIRCADIAN RHYTHM; CYTOTOXICITY; DRUG RECEPTOR BINDING; EMBRYO DEVELOPMENT; HORMONAL THERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; ORPHAN NUCLEAR RECEPTORS;

EID: 77956371051     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0058     Document Type: Review

References (182)

1. van Agthoven T, Sieuwerts A, Meijer-van Gelder M, Look M, Smid M, Veldscholte J, Sleijfer S, Foekens J & Dorssers L 2009a Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. Journal of Clinical Oncology 27 542-549.
2. van Agthoven T, Veldscholte J, Smid M, van Agthoven T, Vreede L, Broertjes M, de Vries I, de Jong D, Sarwari R & Dorssers L 2009b Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Research and Treatment 114 23-30.
3. Akli S, Zheng P, Multani A, Wingate H, Pathak S, Zhang N, Tucker S, Chang S & Keyomarsi K 2004 Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Research 64 3198-3208. (Pubitemid 38581423)
4. Allred D & Medina D 2008 The relevance of mouse models to understanding the development and progression of human breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 279-288.
5. Annicotte J, Chavey C, Servant N, Teyssier J, Bardin A, Licznar A, Badia E, Pujol P, Vignon F, Maudelonde T et al. 2005 The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene. Oncogene 24 8167-8175. (Pubitemid 41759815)
6. Ariazi EA & Jordan VC 2006 Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Current Topics in Medicinal Chemistry 6 203-215.
7. Ariazi EA, Clark GM & Mertz JE 2002 Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Research 62 6510-6518.
8. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC & Mertz JE 2007 Estrogen-related receptor α1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Molecular Cancer Research 5 71-85.
9. Aschrafi A, Meindl N, Firla B, Brandes R & Steinhilber D 2006 Intracellular localization of RORalpha is isoform and cell line-dependent. Biochimica et Biophysica Acta 1763 805-814.
10. Avram D, Ishmael J, Nevrivy D, Peterson V, Lee S, Dowell P & Leid M 1999 Heterodimeric interactions between chicken ovalbumin upstream promoter-transcription factor family members ARP1 and ear2. Journal of Biological Chemistry 274 14331-14336.
11. Barrett T, Troup D, Wilhite S, Ledoux P, Rudnev D, Evangelista C, Kim I, Soboleva A, Tomashevsky M, Marshall K et al. 2009 NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Research 37 D885-D890.
12. Benoit G, Malewicz M & Perlmann T 2004 Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. Trends in Cell Biology 14 369-376. (Pubitemid 38891706)
13. Benoit G, Cooney A, Giguere V, Ingraham H, Lazar M, Muscat G, Perlmann T, Renaud J, Schwabe J, Sladek F et al. 2006 International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacological Reviews 58 798-836.
14. Bianco S, Lanvin O, Tribollet V, Macari C, North S & Vanacker J 2009 Modulating estrogen receptor-related receptor-alpha activity inhibits cell proliferation. Journal of Biological Chemistry 284 23286-23292.
15. Bouchard M, Taniguchi H & Viger R 2005 Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells. Endocrinology 146 4905-4916. (Pubitemid 41446629)
16. Burger K, Mühl B, Harasim T, Rohrmoser M, Malamoussi A, Orban M, Kellner M, Gruber-Eber A, Kremmer E, Hölzel M et al. 2010 Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. Journal of Biological Chemistry 285 12416-12425.
17. Burris T 2008 Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock. Molecular Endocrinology 22 1509-1520. (Pubitemid 351920387)
18. Burris T, Guo W & McCabe E 1996 The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Recent Progress in Hormone Research 51 241-259. (Pubitemid 126476616)
19. Butler WB & Fontana JA 1992 Responses to retinoic acid of tamoxifen-sensitive and -resistant sublines of human breast cancer cell line MCF-7. Cancer Research 52 6164-6167.
20. Buzdar A 2008 Fulvestrant - a novel estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs of Today 44 679-692.
21. Buzdar A 2009 Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Annals of Oncology 20 993-999.
22. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM et al. 2000 The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19 968-988.
23. Carrigan A, Walther R, Salem H, Wu D, Atlas E, Lefebvre Y & Haché R 2007 An active nuclear retention signal in the glucocorticoid receptor functions as a strong inducer of transcriptional activation. Journal of Biological Chemistry 282 10963-10971. (Pubitemid 47100789)
24. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris T & Rastinejad F 2008 Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. Nature 456 350-356.
25. Chen W, Manova K, Weinstein D, Duncan S, Plump A, Prezioso V, Bachvarova R & Darnell JJ 1994 Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes and Development 8 2466-2477. (Pubitemid 24323824)
26. Chen M, Bradley M, Beaven S & Tontonoz P 2006 Phosphorylation of the liver X receptors. FEBS Letters 580 4835-4841.
27. Cheng J, Zhang C & Shapiro DJ 2007 A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17beta-estradiol and 4-hydroxytamoxifen. Endocrinology 148 4634-4641. (Pubitemid 47481539)
28. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T et al. 2006 Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 529-541.
29. Chintamani C, Singhal V, Singh J, Lyall A, Saxena S & Bansal A 2004 Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer? - a prospective clinical study. BMC Cancer 4 48.
30. Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K & Safe S 2005 Activation of Nur77 by selected 1,1-bis(3′-indolyl)-1-(p- substituted phenyl)methanes induces apoptosis through nuclear pathways. Journal of Biological Chemistry 280 24903-24914. (Pubitemid 40934582)
31. Chisamore M, Cunningham M, Flores O, Wilkinson H & Chen J 2009a Characterization of a novel small molecule subtype specific estrogen-related receptor alpha antagonist in MCF-7 breast cancer cells. PLoS ONE 4 e5624.
32. Chisamore M, Wilkinson H, Flores O & Chen J 2009b Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts. Molecular Cancer Therapeutics 8 672-681.
33. Claessens F & Gewirth DT 2004 DNA recognition by nuclear receptors. Essays in Biochemistry 40 59-72.
34. Claessens F, Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G & Rombauts W 2001 Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. Journal of Steroid Biochemistry and Molecular Biology 76 23-30. (Pubitemid 32510664)
35. Clarke R 1996 Animal models of breast cancer: their diversity and role in biomedical research. Breast Cancer Research and Treatment 39 1-6. (Pubitemid 26136499)
36. Clarke R, Leonessa F, Welch JN & Skaar TC 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacological Reviews 53 25-71. (Pubitemid 32173107)
37. Clyne C, Speed C, Zhou J & Simpson E 2002 Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. Journal of Biological Chemistry 277 20591-20597. (Pubitemid 34967360)
38. Clyne C, Kovacic A, Speed C, Zhou J, Pezzi V & Simpson E 2004 Regulation of aromatase expression by the nuclear receptor LRH-1 in adipose tissue. Molecular and Cellular Endocrinology 215 39-44.
39. Collins L, Lee Y, Heinlein C, Liu N, Chen Y, Shyr C, Meshul C, Uno H, Platt K & Chang C 2004 Growth retardation and abnormal maternal behavior in mice lacking testicular orphan nuclear receptor 4. PNAS 101 15058-15063.
40. Conde I, Alfaro J, Fraile B, Ruíz A, Paniagua R & Arenas M 2004 DAX-1 expression in human breast cancer: comparison with estrogen receptors ER-alpha, ER-beta and androgen receptor status. Breast Cancer Research 6 R140-R148.
41. Crago A, Azu M, Tierney S & Morrow M 2010 Randomized clinical trials in breast cancer. Surgical Oncology Clinics of North America 19 33-58.
42. Dae Cho S, Lee S, Chintharlapalli S, Abdelrahim M, Khan S, Yoon K, Kamat A & Safe S 2010 Activation of nerve growth factor-induced ba by methylene-substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth. Molecular Pharmacology 77 396-404.
43. Dai J, Ram P, Yuan L, Spriggs L & Hill S 2001 Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin. Molecular and Cellular Endocrinology 176 111-120. (Pubitemid 32454942)
44. Davies M, Barraclough D, Stewart C, Joyce K, Eccles R, Barraclough R, Rudland P & Sibson D 2008 Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. International Journal of Cancer 123 85-88. (Pubitemid 351705195)
45. Davis L, Harris C, Tang L, Doherty P, Hraber P, Sakai Y, Bocklage T, Doeden K, Hall B, Alsobrook J et al. 2007 Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. Journal of Molecular Diagnostics 9 327-336. (Pubitemid 47305069)
46. Deblois G, Hall J, Perry M, Laganière J, Ghahremani M, Park M, Hallett M & Giguère V 2009 Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. Cancer Research 69 6149-6157.
47. Delhon I, Gutzwiller S, Morvan F, Rangwala S, Wyder L, Evans G, Studer A, Kneissel M & Fournier B 2009 Absence of estrogen receptor-related-alpha increases osteoblastic differentiation and cancellous bone mineral density. Endocrinology 150 4463-4472.
48. Dhillon N & Mudryj M 2002 Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 21 4626-4634. (Pubitemid 34833140)
49. Ding L, Yan J, Zhu J, Zhong H, Lu Q, Wang Z, Huang C & Ye Q 2003a Ligand-independent activation of estrogen receptor alpha by XBP-1. Nucleic Acids Research 31 5266-5274. (Pubitemid 37441894)
50. Ding LH, Ye QN, Zhu JH, Yan JH, Zhong HJ, Wang ZH & Huang CF 2003b XBP-1 enhances the transcriptional activity of estrogen receptor alpha. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao Acta Biochimica et Biophysica Sinica 35 829-833.
51. Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, Walz TM & Polymeropoulos MH 2003 Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Research 63 2194-2199. (Pubitemid 36538626)
52. Duez H & Staels B 2009 Rev-erb-alpha: an integrator of circadian rhythms and metabolism. Journal of Applied Physiology 107 1972-1980.
53. Dunker AK, Cortese MS, Romero P, Iakoucheva LM & Uversky VN 2005 Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS Journal 272 5129-5148. (Pubitemid 41503146)
54. Ellis M, Miller W, Tao Y, Evans D, Chaudri Ross H, Miki Y, Suzuki T & Sasano H 2009 Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Research and Treatment 116 371-378.
55. Ethier SP, Mahacek ML, Gullick WJ, Frank TS & Weber BL 1993 Differential isolation of normal liminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Research 53 627-635.
56. Fang Y, Yan J, Ding L, Liu Y, Zhu J, Huang C, Zhao H, Lu Q, Zhang X, Yang X et al. 2004 XBP-1 increases ERalpha transcriptional activity through regulation of large-scale chromatin unfolding. Biochemical and Biophysical Research Communications 323 269-274. (Pubitemid 39200679)
57. Faulds M, Olsen H, Helguero L, Gustafsson J & Haldosén L 2004 Estrogen receptor functional activity changes during differentiation of mammary epithelial cells. Molecular Endocrinology 18 412-421. (Pubitemid 38185881)
58. Fayard E, Auwerx J & Schoonjans K 2004 LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends in Cell Biology 14 250-260.
59. Feldman DE, Chauhan V & Koong AC 2005 The unfolded protein response: a novel component of the hypoxic stress response in tumors. Molecular Cancer Research 3 597-605.
60. Ferri K & Kroemer G 2001 Mitochondria - the suicide organelles. BioEssays 23 111-115.
61. Flaig R, Greschik H, Peluso-Iltis C & Moras D 2005 Structural basis for the cell-specific activities of the NGFI-B and the Nurr1 ligand-binding domain. Journal of Biological Chemistry 280 19250-19258. (Pubitemid 41379632)
62. Francis G, Fayard E, Picard F & Auwerx J 2003 Nuclear receptors and the control of metabolism. Annual Review of Physiology 65 261-311.
63. Freedman LP, Luisi BF, Korszun ZR, Basavappa R, Sigler PB & Yamamoto KR 1988 The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain. Nature 334 543-546.
64. Froy O 2010 Metabolism and circadian rhythms - implications for obesity. Endocrine Reviews 31 1-24.
65. Gaillard S, Grasfeder L, Haeffele C, Lobenhofer E, Chu T, Wolfinger R, Kazmin D, Koves T, Muoio D, Chang C et al. 2006 Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs. Molecular Cell 24 797-803.
66. Gaillard S, Dwyer M & McDonnell D 2007 Definition of the molecular basis for estrogen receptor-related receptoralpha-cofactor interactions. Molecular Endocrinology 21 62-76.
67. Garza AM, Khan SH & Kumar R 2010 Site-specific phosphorylation induces functionally active conformation in the intrinsically disordered N-terminal activation function (AF1) domain of the glucocorticoid receptor. Molecular and Cellular Biology 30 220-230.
68. Gearhart M, Holmbeck S, Evans R, Dyson H & Wright P 2003 Monomeric complex of human orphan estrogen related receptor-2 with DNA: a pseudo-dimer interface mediates extended half-site recognition. Journal of Molecular Biology 327 819-832. (Pubitemid 36315921)
69. Giguere V 2008 Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocrine Reviews 29 677-696.
70. Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M & Clarke R 2007 Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB Journal 21 4013-4027. (Pubitemid 350232358)
71. Greschik H, Wurtz JM, Sanglier S, Bourguet W, van Dorsselaer A, Moras D & Renaud JP 2002 Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Molecular Cell 9 303-313.
72. Greschik H, Flaig R, Renaud JP & Moras D 2004 Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. Journal of Biological Chemistry 279 33639-33646.
73. Gu Z, Lee RY, Skaar TC, Bouker KB, Welch JN, Lu J, Liu A, Zhu Y, Davis N, Leonessa F et al. 2002 Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182,780). Cancer Research 62 3428-3437.
74. Gupta P, Park S, Farooqui M & Wei L 2007 Orphan nuclear receptor TR2, a mediator of preadipocyte proliferation, is differentially regulated by RA through exchange of coactivator PCAF with corepressor RIP140 on a platform molecule GRIP1. Nucleic Acids Research 35 2269-2282. (Pubitemid 47078746)
75. Gurates B, Sebastian S, Yang S, Zhou J, Tamura M, Fang Z, Suzuki T, Sasano H & Bulun S 2002 WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells. Journal of Clinical Endocrinology and Metabolism 87 4369-4377.
76. Gurates B, Amsterdam A, Tamura M, Yang S, Zhou J, Fang Z, Amin S, Sebastian S & Bulun S 2003 WT1 and DAX-1 regulate SF-1-mediated human P450arom gene expression in gonadal cells. Molecular and Cellular Endocrinology 208 61-75. (Pubitemid 37315839)
77. Hall JM & McDonnell DP 2005 Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Molecular Interventions 5 343-357.
78. Heck S, Rom J, Thewes V, Becker N, Blume B, Sinn H, Deuschle U, Sohn C, Schneeweiss A & Lichter P 2009 Estrogen-related receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma. Cancer Research 69 5186-5193.
79. Helguero L, Hedengran Faulds M, Förster C, Gustafsson J & Haldosén L 2006 DAX-1 expression is regulated during mammary epithelial cell differentiation. Endocrinology 147 3249-3259. (Pubitemid 43904302)
80. Horard B & Vanacker JM 2003 Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. Journal of Molecular Endocrinology 31 349-357. (Pubitemid 38054510)
81. Hsieh J, Whitfield G, Oza A, Dang H, Price J, Galligan M, Jurutka P, Thompson P, Haussler C & Haussler M 1999 Characterization of unique DNA-binding and transcriptional-activation functions in the carboxyl-terminal extension of the zinc finger region in the human vitamin D receptor. Biochemistry 38 16347-16358. (Pubitemid 129520558)
82. Hu Y, Shyr C, Che W, Mu X, Kim E & Chang C 2002 Suppression of estrogen receptor-mediated transcription and cell growth by interaction with TR2 orphan receptor. Journal of Biological Chemistry 277 33571-33579.
83. Huppunen J, Wohlfahrt G & Aarnisalo P 2004 Requirements for transcriptional regulation by the orphan nuclear receptor ERRgamma. Molecular and Cellular Endocrinology 219 151-160. (Pubitemid 38659522)
84. Hwang E, Lee J, Jeong J, Park J, Yang Y, Lim J, Kim J, Baek S & Kim K 2009 SUMOylation of RORalpha potentiates transcriptional activation function. Biochemical and Biophysical Research Communications 378 513-517.
85. Jemal A, Siegel R, Ward E, Hao Y, Xu J & Thun M 2009 Cancer statistics, 2009. CA: A Cancer Journal for Clinicians 59 225-249.
86. Jeong Y & Mangelsdorf DJ 2009 Nuclear receptor regulation of stemness and stem cell differentiation. Experimental & Molecular Medicine 41 525-537.
87. Jetten A 2004 Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs). Current Drug Targets. Inflammation and Allergy 3 395-412. (Pubitemid 39534775)
88. Johansson L, Thomsen J, Damdimopoulos A, Spyrou G, Gustafsson J & Treuter E 1999 The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ERalpha and ERbeta. Journal of Biological Chemistry 274 345-353. (Pubitemid 29035068)
89. Johnston S 2009 Enhancing the efficacy of hormonal agents with selected targeted agents. Clinical Breast Cancer 9 (Supplement 1) S28-S36.
90. Kallen J, Schlaeppi J, Bitsch F, Delhon I & Fournier B 2004 Crystal structure of the human RORalpha ligand binding domain in complex with cholesterol sulfate at 2.2 A. Journal of Biological Chemistry 279 14033-14038. (Pubitemid 38468938)
91. Kang H, Angers M, Beak J, Wu X, Gimble J, Wada T, Xie W, Collins J, Grissom S & Jetten A 2007 Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiological Genomics 31 281-294. (Pubitemid 350014406)
92. Kim G, Lee G, Nedumaran B, Park Y, Kim K, Park S, Lee Y, Kim J & Choi H 2008 The orphan nuclear receptor DAX-1 acts as a novel transcriptional corepressor of PPARgamma. Biochemical and Biophysical Research Communications 370 264-268.
93. Klinge C 1999 Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF). Journal of Steroid Biochemistry and Molecular Biology 71 1-19.
94. Klinge C, Silver B, Driscoll M, Sathya G, Bambara R & Hilf R 1997 Chicken ovalbumin upstream promoter-transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression. Journal of Biological Chemistry 272 31465-31474. (Pubitemid 28013286)
95. Kong W, Jiang X & Mercer W 2009a Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. Cancer Biology & Therapy 8 555-563.
96. Kong X, Fan H, Liu X, Wang R, Liang J, Gupta N, Chen Y, Fang F & Chang Y 2009b Peroxisome proliferator-activated receptor gamma coactivator-1alpha enhances antiproliferative activity of 5′-deoxy-5- fluorouridine in cancer cells through induction of uridine phosphorylase. Molecular Pharmacology 76 854-860.
97. Koritschoner N, Madruga J, Knespel S, Blendinger G, Anzinger B, Otto A, Zenke M & Bartůněk P 2001 The nuclear orphan receptor TR4 promotes proliferation of myeloid progenitor cells. Cell Growth & Differentiation 12 563-572. (Pubitemid 33095579)
98. Kovacic A, Speed C, Simpson E & Clyne C 2004 Inhibition of aromatase transcription via promoter II by short heterodimer partner in human preadipocytes. Molecular Endocrinology 18 252-259. (Pubitemid 38073169)
99. Krasowski MD, Reschly EJ & Ekins S 2008 Intrinsic disorder in nuclear hormone receptors. Journal of Proteome Research 7 4359-4372.
100. Kraus RJ, Ariazi EA, Farrell ML & Mertz JE 2002 Estrogenrelated receptor alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells. Journal of Biological Chemistry 277 24826-24834.
101. Kudo K, Xi Y, Wang Y, Song B, Chu E, Ju J & Russo J 2010 Translational control analysis by translationally active RNA capture/microarray analysis (TrIP-Chip). Nucleic Acids Research 38 e104.
102. Kumar R & Litwack G 2009 Structural and functional relationships of the steroid hormone receptors' N-terminal transactivation domain. Steroids 74 877-883.
103. Lacroix M & Leclercq G 2004 About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Molecular and Cellular Endocrinology 219 1-7. (Pubitemid 38659520)
104. Lanvin O, Bianco S, Kersual N, Chalbos D & Vanacker J 2007 Potentiation of ICI182,780 (Fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790. Journal of Biological Chemistry 282 28328-28334.
105. Le Dily F, Métivier R, Guéguen M, Le Péron C, Flouriot G, Tas P & Pakdel F 2008 COUP-TFI modulates estrogen signaling and influences proliferation, survival and migration of breast cancer cells. Breast Cancer Research and Treatment 110 69-83.
106. Lee Y, Lee H & Chang C 2002 Recent advances in the TR2 and TR4 orphan receptors of the nuclear receptor superfamily. Journal of Steroid Biochemistry and Molecular Biology 81 291-308. (Pubitemid 35279114)
107. Li Y, Choi M, Cavey G, Daugherty J, Suino K, Kovach A, Bingham N, Kliewer S & Xu H 2005 Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Molecular Cell 17 491-502.
108. Lin D & Chang C 1996 p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. Journal of Biological Chemistry 271 14649-14652. (Pubitemid 26194934)
109. Liu D, Zhang Z, Gladwell W & Teng C 2003 Estrogen stimulates estrogen-related receptor alpha gene expression through conserved hormone response elements. Endocrinology 144 4894-4904. (Pubitemid 37378404)
110. Liu N, Lin W, Kim E, Collins L, Lin H, Yu I, Sparks J, Chen L, Lee Y & Chang C 2007 Loss of TR4 orphan nuclear receptor reduces phosphoenolpyruvate carboxykinase-mediated gluconeogenesis. Diabetes 56 2901-2909. (Pubitemid 350223624)
111. Lu D, Kiriyama Y, Lee K & Giguère V 2001 Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Research 61 6755-6761.
112. Lykkesfeldt A, Henriksen K, Rasmussen B, Sasano H, Evans D, Møller S, Ejlertsen B & Mouridsen H 2009 In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer. BMC Cancer 9 185.
113. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT et al. 2004 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 607-616.
114. Macciò A, Madeddu C & Mantovani G 2009 Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obesity Reviews 10 660-670.
115. Macedo L, Sabnis G & Brodie A 2009 Aromatase inhibitors and breast cancer. Annals of the New York Academy of Sciences 1155 162-173.
116. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. 1995 The nuclear receptor superfamily: the second decade. Cell 83 835-839.
117. Marcotte R & Muller W 2008 Signal transduction in transgenic mouse models of human breast cancer - implications for human breast cancer. Journal of Mammary Gland Biology and Neoplasia 13 323-335.
118. Maring J, Groen H, Wachters F, Uges D & de Vries E 2005 Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics Journal 5 226-243. (Pubitemid 41131715)
119. Markićević M, Petrović A, Kanjer K, Nesković-Konstantinović Z & Nikolić- Vukosavujević D 2008 Estrogen-regulated cut-off values of pS2 and cathepsin D expression in breast carcinomas. Advances in Experimental Medicine and Biology 617 341-348.
120. Métivier R, Gay F, Hübner M, Flouriot G, Salbert G, Gannon F, Kah O & Pakdel F 2002 Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1 through Ser118 phosphorylation by MAPK. EMBO Journal 21 3443-3453. (Pubitemid 34760576)
121. Miki Y, Clyne C, Suzuki T, Moriya T, Shibuya R, Nakamura Y, Ishida T, Yabuki N, Kitada K, Hayashi S et al. 2006 Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of in situ steroidogenesis. Cancer Letters 244 24-33.
122. Minezaki Y, Homma K, Kinjo AR & Nishikawa K 2006 Human transcription factors contain a high fraction of intrinsically disordered regions essential for transcriptional regulation. Journal of Molecular Biology 359 1137-1149. (Pubitemid 43831930)
123. Moll U, Marchenko N & Zhang X 2006 p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 25 4725-4743. (Pubitemid 44187622)
124. Moral R, Wang R, Russo IH, Lamartiniere CA, Pereira J & Russo J 2008 Effect of prenatal exposure to the endocrine disruptor bisphenol A on mammary gland morphology and gene expression signature. Journal of Endocrinology 196 101-112. (Pubitemid 351234575)
125. Moré E, Fellner T, Doppelmayr H, Hauser-Kronberger C, Dandachi N, Obrist P, Sandhofer F & Paulweber B 2003 Activation of the MAP kinase pathway induces chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) expression in human breast cancer cell lines. Journal of Endocrinology 176 83-94. (Pubitemid 36163569)
126. Musgrove E & Sutherland R 2009 Biological determinants of endocrine resistance in breast cancer. Nature Reviews. Cancer 9 631-643.
127. Nakshatri H, Mendonca M, Bhat-Nakshatri P, Patel N, Goulet RJ & Cornetta K 2000 The orphan receptor COUP-TFII regulates G2/M progression of breast cancer cells by modulating the expression/activity of p21(WAF1/CIP1), cyclin D1, and cdk2. Biochemical and Biophysical Research Communications 270 1144-1153.
128. Novac N & Heinzel T 2004 Nuclear receptors: overview and classification. Current Drug Targets. Inflammation and Allergy 3 335-346.
129. Odawara H, Iwasaki T, Horiguchi J, Rokutanda N, Hirooka K, Miyazaki W, Koibuchi Y, Shimokawa N, Iino Y, Takeyoshi I et al. 2009 Activation of aromatase expression by retinoic acid receptor-related orphan receptor (ROR) alpha in breast cancer cells: identification of a novel ROR response element. Journal of Biological Chemistry 284 17711-17719.
130. Ohkubo T, Ohkura N, Maruyama K, Sasaki K, Nagasaki K, Hanzawa H, Tsukada T & Yamaguchi K 2000 Early induction of the orphan nuclear receptor NOR-1 during cell death of the human breast cancer cell line MCF-7. Molecular and Cellular Endocrinology 162 151-156.
131. Olopade O, Grushko T, Nanda R & Huo D 2008 Advances in breast cancer: pathways to personalized medicine. Clinical Cancer Research 14 7988-7999.
132. O'Malley BW & Kumar R 2009 Nuclear receptor coregulators in cancer biology. Cancer Research 69 8217-8222.
133. Orlando F & Brown K 2009 Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Annals of Surgical Oncology 16 2270-2279.
134. Ortlund E, Lee Y, Solomon I, Hager J, Safi R, Choi Y, Guan Z, Tripathy A, Raetz C, McDonnell D et al. 2005 Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP. Nature Structural & Molecular Biology 12 357-363.
135. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817-2826.
136. Parton M, Krajewski S, Smith I, Krajewska M, Archer C, Naito M, Ahern R, Reed J & Dowsett M 2002 Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clinical Cancer Research 8 2100-2108.
137. Pereira F, Qiu Y, Zhou G, Tsai M & Tsai S 1999 The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. Genes and Development 13 1037-1049. (Pubitemid 29200986)
138. Rae JM, Ramus SJ, Waltham M, Armes JE, Campbell IG, Clarke R, Barndt RJ, Johnson MD & Thompson EW 2004 Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clinical & Experimental Metastasis 21 543-552.
139. Rajhans R, Nair H, Nair S, Cortez V, Ikuko K, Kirma N, Zhou D, Holden A, Brann D, Chen S et al. 2008 Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. Molecular Endocrinology 22 649-664.
140. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T et al. 2006 FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas 1 7372. Clinical Cancer Research 12 6652-6662.
141. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A & Chinnaiyan AM 2004 ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6 1-6. (Pubitemid 38391943)
142. Riggins R, Bouton AH, Liu MC & Clarke R 2005 Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitamins and Hormones 71 201-237. (Pubitemid 43631307)
143. Riggins RB, Schrecengost RS, Guerrero MS & Bouton AH 2007 Pathways to tamoxifen resistance. Cancer Letters 256 1-24.
144. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J et al. 2008 ERRγ mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Research 68 8908-8917.
145. Riggs K, Wickramasinghe N, Cochrum R, Watts M & Klinge C 2006 Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifenresistant breast cancer cells. Cancer Research 66 10188-10198. (Pubitemid 44672074)
146. Robinson-Rechavi M, Garcia HE & Laudet V 2003 The nuclear receptor superfamily. Journal of Cell Science 116 585-586.
147. Safi R, Kovacic A, Gaillard S, Murata Y, Simpson E, McDonnell D & Clyne C 2005 Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy. Cancer Research 65 11762-11770. (Pubitemid 41821738)
148. Sahar S & Sassone-Corsi P 2009 Metabolism and cancer: the circadian clock connection. Nature Reviews. Cancer 9 886-896.
149. Santen R, Brodie H, Simpson E, Siiteri P & Brodie A 2009 History of aromatase: saga of an important biological mediator and therapeutic target. Endocrine Reviews 30 343-375.
150. Schoenmakers E, Alen P, Verrijdt G, Peeters B, Verhoeven G, Rombauts W & Claessens F 1999 Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains. Biochemical Journal 341 515-521. (Pubitemid 29389179)
151. Schultz J, Loven M, Melvin V, Edwards D & Nardulli A 2002 Differential modulation of DNA conformation by estrogen receptors alpha and beta. Journal of Biological Chemistry 277 8702-8707.
152. Sentis S, Le Romancer M, Bianchin C, Rostan M & Corbo L 2005 Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Molecular Endocrinology 19 2671-2684.
153. Seol W, Choi H & Moore D 1996 An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 272 1336-1339.
154. Shajahan A, Riggins R & Clarke R 2008 Apoptosis, cell death, and breast cancer. In Breast Cancer: Prognosis, Treatment, and Prevention, edn 2, ch 8, pp 137-155. Ed J Pasqualini. New York, NY, USA: Informa Healthcare.
155. Shyr C, Hu Y, Kim E & Chang C 2002 Modulation of estrogen receptor-mediated transactivation by orphan receptor TR4 in MCF-7 cells. Journal of Biological Chemistry 277 14622-14628.
156. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van de RM, Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874.
157. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100 8418-8423.
158. Stein R & McDonnell D 2006 Estrogen-related receptor alpha as a therapeutic target in cancer. Endocrine-Related Cancer 13 (Supplement 1) S25-S32. (Pubitemid 46219246)
159. Stein R, Chang C, Kazmin D, Way J, Schroeder T, Wergin M, Dewhirst M & McDonnell D 2008 Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Research 68 8805-8812.
160. Stein R, Gaillard S & McDonnell D 2009 Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 114 106-112.
161. Surowiak P, Materna V, Györffy B, Matkowski R, Wojnar A, Maciejczyk A, Paluchowski P, Dziegiel P, Pudełko M, Kornafel J et al. 2006 Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. British Journal of Cancer 95 339-346.
162. Suzuki T, Miki Y, Moriya T, Shimada N, Ishida T, Hirakawa H, Ohuchi N & Sasano H 2004 Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Research 64 4670-4676.
163. Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, Jacobsen BM, Bain DL & Horwitz KB 2003 Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. Journal of Steroid Biochemistry and Molecular Biology 85 209-219.
164. Tamasi V, Miller KK, Ripp SL, Vila E, Geoghagen TE & Prough RA 2008 Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators. Molecular Pharmacology 73 968-976.
165. Tanabe O, Shen Y, Liu Q, Campbell A, Kuroha T, Yamamoto M & Engel J 2007 The TR2 and TR4 orphan nuclear receptors repress Gata1 transcription. Genes and Development 21 2832-2844.
166. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R & Bieche I 2006 Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocrine-Related Cancer 13 1109-1120.
167. Tremblay AM & Giguere V 2007 The NR3B subgroup: an ovERRview. Nuclear Receptor Signaling 5 e009.
168. Tremblay AM, Wilson BJ, Yang XJ & Giguere V 2008 Phosphorylation- dependent sumoylation regulates estrogen-related receptor-alpha and -gamma transcriptional activity through a synergy control motif. Molecular Endocrinology 22 570-584.
169. Vu EH, Kraus RJ & Mertz JE 2007 Phosphorylation-dependent sumoylation of estrogen-related receptor alpha1. Biochemistry 46 9795-9804.
170. Wang Z, Jeffs B, Ito M, Achermann J, Yu R, Hales D & Jameson J 2001 Aromatase (Cyp19) expression is up-regulated by targeted disruption of Dax1. PNAS 98 7988-7993.
171. Wang Z, Benoit G, Liu J, Prasad S, Aarnisalo P, Liu X, Xu H, Walker N & Perlmann T 2003 Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 423 555-560.
172. Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG & Glass CK 1998 Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 395 199-202.
173. Wilson B & Giguère V 2008 Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Molecular Cancer 7 49.
174. Wilson B, Tremblay A, Deblois G, Sylvain-Drolet G & Giguère V 2010 An acetylation switch modulates the transcriptional activity of estrogen-related receptor a. Molecular Endocrinology 24 1349-1358.
175. Wisely G, Miller A, Davis R, Thornquest AJ, Johnson R, Spitzer T, Sefler A, Shearer B, Moore J, Willson T et al. 2002 Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure 10 1225-1234. (Pubitemid 35254011)
176. Wu F, Wang J, Wang Y, Kwok T, Kong S & Wong C 2009 Estrogen-related receptor alpha (ERRalpha) inverse agonist XCT-790 induces cell death in chemotherapeutic resistant cancer cells. Chemico-Biological Interactions 181 236-242.
177. Wurtz J, Bourguet W, Renaud J, Vivat V, Chambon P, Moras D & Gronemeyer H 1996 A canonical structure for the ligand-binding domain of nuclear receptors. Nature Structural Biology 3 87-94.
178. Zhang H, Thomsen J, Johansson L, Gustafsson J & Treuter E 2000 DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. Journal of Biological Chemistry 275 39855-39859. (Pubitemid 32065755)
179. Zhang T, Jia N, Fei E, Wang P, Liao Z, Ding L, Yan M, Nukina N, Zhou J & Wang G 2007 Nurr1 is phosphorylated by ERK2 in vitro and its phosphorylation upregulates tyrosine hydroxylase expression in SH-SY5Y cells. Neuroscience Letters 423 118-122. (Pubitemid 47259592)
180. Zhang T, Wang P, Ren H, Fan J & Wang G 2009 NGFI-B nuclear orphan receptor Nurr1 interacts with p53 and suppresses its transcriptional activity. Molecular Cancer Research 7 1408-1415.
181. Zhou J, Suzuki T, Kovacic A, Saito R, Miki Y, Ishida T, Moriya T, Simpson E, Sasano H & Clyne C 2005 Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Research 65 657-663.
182. Zhu Y, McAvoy S, Kuhn R & Smith D 2006 RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 25 2901-2908. (Pubitemid 43739240)